AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01918761
Drug: Dacomitinib, Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)
Trial: NCT00166452
Drug: Lenalidamide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02715232
Drug: Lynestrenol
RxNorm normalized name: lynestrenol
DrugBank: Lynestrenol (DB12474)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-3 tablets/day, if menstruation still occurs
Trial: NCT02715232
Drug: Cyproterone Acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg daily
Trial: NCT02715232
Drug: Triptorelin acetate
RxNorm normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
Trial: NCT01321437
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.
Trial: NCT01009515
Drug: Paclitaxel, carboplatin, temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combination chemotherapy was administered for up to 6 cycles
Trial: NCT00456482
Drug: Fluocinolone Acetonide 0.59mg
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone Acetonide Intravitreal Implant 0.59 mg
Trial: NCT00456482
Drug: Fluocinolone Acetonide 2.1mg
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone Acetonide Intravitreal Implant 2.1 mg
Trial: NCT02675374
Drug: dexchlorpheniramine (Polaramine®) injection
RxNorm normalized name: dexchlorpheniramine maleate Oral Tablet [Polaramine]
DrugBank: Dexchlorpheniramine maleate (DB09555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
Trial: NCT02462486
Drug: Abicipar Pegol
RxNorm normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abicipar pegol intravitreal injection.
Trial: NCT02462486
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab intravitreal injection.
Trial: NCT00075686
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 IV over 30 minutes
Trial: NCT01767610
Drug: micronized fenofibrate 160mg
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01767610
Drug: pitavastatin Ca 2mg
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01767610
Drug: micronized fenofibrate 160mg plus pitavastatin Ca 2mg
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01216410
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
Trial: NCT01216410
Drug: Phenylephrine infusion
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic phenylephrine infusion after spinal and placebo antiemetics
Trial: NCT00983528
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose Escalation~Cycle 1 (30 days or until alemtuzumab completed) Clofarabine 10,20,30 or 40 mg/m2 days 5-9~Cycle 2 and subsequent cycles (administered no more frequently than every 28 days) 10,20,30 or 40 mg/m2 days 1-5
Trial: NCT04194554
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: given PO per dose escalation schedule
Trial: NCT04194554
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22.5 mg q3 month
Trial: NCT04194554
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg daily
Trial: NCT01558830
Drug: ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
Trial: NCT03017950
Drug: CKD-330
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03799848
Drug: Vadadustat
RxNorm normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral tablet
Trial: NCT03091257
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered Orally BID
Trial: NCT03091257
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered Orally once daily
Trial: NCT00275639
Drug: Cozaar
RxNorm normalized name: Cozaar
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00924586
Drug: ONO-1101
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for one minute IV
Trial: NCT00924586
Drug: ONO-1101
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg/kg for one minute IV
Trial: NCT01362673
Drug: PF-04171327
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single 5 mg dose as one 5 mg tablet
Trial: NCT01362673
Drug: PF-04171327
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single 10 mg dose as one 10 mg tablet
Trial: NCT01362673
Drug: PF-04171327
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single 30 mg dose as three 10 mg tablets
Trial: NCT03017950
Drug: CKD-330 + D086
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00479661
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous infusion
Trial: NCT00479661
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous infusion
Trial: NCT01362673
Drug: PF-04171327
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral multiple 20 mg doses as two 10 mg tablets for 12 days
Trial: NCT01034462
Drug: Levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
Trial: NCT00492687
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02546050
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00492687
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00492687
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03255044
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin administered as well as standard heart failure therapy
Trial: NCT04080596
Drug: Dorzagliatin
RxNorm normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GKA for T2DM currently under clinical development
Trial: NCT03710044
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks.~Responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).~In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks.
Trial: NCT01706263
Drug: MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Available over the counter.
Trial: NCT00233155
Drug: Capsaicin Dermal Patch
RxNorm normalized name: capsaicin Medicated Patch
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02063217
Drug: Sodium Oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate h.s.
Trial: NCT00273416
Drug: PF-00592379
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00273416
Drug: Sildenafil 100mg
RxNorm normalized name: sildenafil 100 MG
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00559364
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
Trial: NCT04126343
Drug: Padsevonil
RxNorm normalized name: Padsevonil
DrugBank: Padsevonil (DB14977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period
Trial: NCT04126343
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive moxifloxacin once during the Treatment Period
Trial: NCT04561336
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: avelumab in combination with cetuximab
Trial: NCT04561336
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: avelumab in combination with cetuximab
Trial: NCT01358084
Drug: NGR-hTNF
RxNorm normalized name: NGR-hTNF
DrugBank: Tengonermin (DB16689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
Trial: NCT00398684
Drug: Single dose nevirapine to the mother and to the child
RxNorm normalized name: THE-630
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
Trial: NCT00398684
Drug: Single dose nevirapine to the mother and placebo to the child
RxNorm normalized name: THE-630
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
Trial: NCT00398684
Drug: Single dose placebo to the mother and to the child
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
Trial: NCT01235442
Drug: 1=Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
Trial: NCT01235442
Drug: 2=Clobetasol propionate foam
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
Trial: NCT04490707
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Azacitidine
Trial: NCT04490707
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Lenalidomide
Trial: NCT00782561
Drug: FG-3019
RxNorm normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
Trial: NCT01118845
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
Trial: NCT02743806
Drug: Vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab IV infusion
Trial: NCT02574338
Drug: prostaglandin E1 analogue
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravaginal misoprostol
Trial: NCT02979691
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT04143295
Drug: Diiodothyropropionic acid (DITPA)
RxNorm normalized name: 3,5-diiodothyropropionic acid
DrugBank: 3,5-diiodothyropropionic acid (DB12629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Administration
Trial: NCT00244829
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04440280
Drug: Visine Dry Eye Relief eye drops
RxNorm normalized name: POLYETHYLENE GLYCOL 400 10 mg in 1 mL OPHTHALMIC SOLUTION/ DROPS [Visine Dry Eye Relief Eye Drops]
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visine Tears Dry Eye Relief artificial tears ophthalmic solution
Trial: NCT02402491
Drug: 12 months of P2Y12 receptor antagonist
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
Trial: NCT02402491
Drug: 24 months of P2Y12 receptor antagonist
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
Trial: NCT02402491
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
Trial: NCT01731886
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.
Trial: NCT01731886
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
Trial: NCT01731886
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects undergoing autologous peripheral blood stem cell transplant will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2.
Trial: NCT01731886
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
Trial: NCT02289690
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally twice a day according to the dosing schedule.
Trial: NCT02289690
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL\*minute.
Trial: NCT02289690
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².
Trial: NCT01731886
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesna will be provided with the cyclophosphamide.
Trial: NCT00929058
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intra-arterial infusion during 6 minutes
Trial: NCT01310361
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01020526
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral capsule 75-450 mg/day
Trial: NCT00056381
Drug: Anidulafungin
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00426179
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03573817
Drug: Revefenacin
RxNorm normalized name: Revefenacin
DrugBank: Revefenacin (DB11855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Revefenacin is administered via a nebulizer.
Trial: NCT03573817
Drug: Formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered sequentially in both revefenacin and placebo arms using a nebulizer.
Trial: NCT02013531
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
Trial: NCT00094367
Drug: Abacavir/Lamivudine
RxNorm normalized name: ABACAVIR/LAMIVUDINE
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04273217
Drug: AV-1
RxNorm normalized name: AV-101
DrugBank: AV-101 (DB12878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, administered by IV infusion (volume: 250 mL)
Trial: NCT03139240
Drug: Oxycodone 10mg oral
RxNorm normalized name: oxycodone 10 MG
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
Trial: NCT01396421
Drug: OPC-34712 [Brexpiprazole] High Dose
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Higher dose, tablet, once daily, for six weeks
Trial: NCT01396421
Drug: Experimental: OPC-34712 [Brexpiprazole] Middle Dose
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Middle dose, tablet, once daily, for six weeks
Trial: NCT01396421
Drug: Experimental: OPC-34712 [Brexpiprazole] Low Dose
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lower dose, tablet, once daily, for six weeks
Trial: NCT00982631
Drug: Temsirolimus/PLD
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
Trial: NCT04117893
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will start on duloxetine 30 mg per day for one week and then titrated up to duloxetine 60mg per day for 23 weeks.
Trial: NCT03182751
Drug: Tranexamic Acid (TXA)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours
Trial: NCT00957216
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg wafers; 2 wafers 4 times a day